Clinical Trial Update: Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies [Phase 3]

View source ↗

Summary

A Phase 3 long-term extension study of zanubrutinib (BGB-3111) regimens is being conducted in participants with B-cell malignancies; the trial is currently ACTI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: B-cell Malignancies | Phase 3 | Status: ACTIVE_NOT_RECRUITING